ABSTRACT
There is a plethora of biomarkers proposed and being researched in the field of sepsis. The complex pathophysiology of sepsis involves many mediators of inflammation pertaining to coagulation, complement, contact system activation, inflammation, apoptosis, etc. Markers related to those processes can gauge the degree of sepsis. Compared with localized pathology, the systemic nature and involvement of multiple organs in sepsis gives scope for numerous potential biomarkers. There is no 'gold standard' for the diagnosis of sepsis. Currently available/in-research biomarkers are compared for their efficacy with methods used to diagnose and monitor sepsis such as combination of clinical signs and available laboratory variables. An arbitrary classification of these biomarkers is made and the literature surrounding these markers and their efficacy in diagnosis of sepsis is reviewed.
ABSTRACT
Patients with malignant bone tumours often come at a very late stage of disease to Medical Colleges. Because of their high mortality rate, accurate & quick diagnosis of these lesions become essential, inspite of clinical, radiological and histopathological assessments. A simple, inexpensive, safe & least traumatic technique-fine needle aspiration cytology (FNAC) in diagnosis of 55 malignant bone tumours was carried out. Specific tumour types metastatic tumour (12), Giant cell tumour (12), Ewing's sarcoma (10), Osteosarcoma (7), Multiple myeloma (7), Chordoma (3), Chondrosarcoma (3) and Fibrosarcoma (1) could be ascertained in 87.2% whereas malignant tumour was suggested in 94.5% (52 cases).